• Profile
Close

Immunogenicity and safety of a new live attenuated herpes zoster vaccine (NBP608) compared to Zostavax in healthy adults aged 50 years and older

Vaccine May 25, 2019

Choi WS, et al. – Researchers compared NBP608 with Zostavax in terms of immunogenicity and safety in healthy adults aged 50 years or older enrolled in this multicenter, randomized, double-blinded, active-controlled, parallel-group clinical trial. The screening included 845 subjects, among whom 413 (NBP608 group) and 411 (comparator group) received vaccination. At 6 weeks following vaccination, the interferon-γ and interleukin-2 enzyme-linked immunosorbent spot assays-determined geometric mean spot numbers did not differ statistically significantly between the two groups. The incidence of adverse events within 6 weeks following vaccination was 49.82%, 50.73% in the NBP608 group, and 48.91% in the comparator group. With regard to immunogenicity, NBP608 was found to be non-inferior to Zostavax. Furthermore, administration of NBP608 to adults aged 50 years or older was safe in this study.

Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay